Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $22.2 million.

  • Summit Therapeutics' Accounts Payables rose 58404.06% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 58404.06%. This contributed to the annual value of $4.6 million for FY2024, which is 7382.83% up from last year.
  • Summit Therapeutics' Accounts Payables amounted to $22.2 million in Q3 2025, which was up 58404.06% from $23.0 million recorded in Q2 2025.
  • Summit Therapeutics' Accounts Payables' 5-year high stood at $23.0 million during Q2 2025, with a 5-year trough of $355000.0 in Q4 2022.
  • Over the past 5 years, Summit Therapeutics' median Accounts Payables value was $4.1 million (recorded in 2021), while the average stood at $5.7 million.
  • In the last 5 years, Summit Therapeutics' Accounts Payables tumbled by 9188.39% in 2022 and then skyrocketed by 79732.39% in 2024.
  • Over the past 5 years, Summit Therapeutics' Accounts Payables (Quarter) stood at $4.4 million in 2021, then plummeted by 91.88% to $355000.0 in 2022, then surged by 651.27% to $2.7 million in 2023, then surged by 73.83% to $4.6 million in 2024, then surged by 379.83% to $22.2 million in 2025.
  • Its last three reported values are $22.2 million in Q3 2025, $23.0 million for Q2 2025, and $5.0 million during Q1 2025.